

QSPainRelief

Effective combinational treatment of chronic pain in individual patients, by an innovative quantitative systems pharmacology pain relief approach.

H2020 – 848068

D 9.2 - Go-online of the public project website

Dissemination level	PUBLIC
Contractual date of delivery	30/04/2020
Actual date of delivery	27/04/2020
Type	Website
Version	1.0
Filename	QSPainRelief_Deliverable report_D9.2
Workpackage	9
Workpackage leader	concentris (Dr. Nina Donner)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 848068. This report reflects only the author's views and the Commission is not responsible for any use that may be made of the information it contains.

Author list

Organisation	Name	Contact information
concentris	Dr. Nina Donner	nina.donner@concentris.de
ULEI	Prof. Dr. Liesbeth de Lange	ecmdelange@lacdr.leidenuniv.nl
ISB	Robert Carr	Robert-Carr1@In-Silico-Biosciences.com

Table of Contents


1. Executive Summary.....	4
2. Deliverable report.....	5
4. Conclusion	7

1. Executive Summary

On April 27th 2020, the full-flashed project website (<https://qspainrelief.eu/>) went live as part of task 2 of work package 09. This full-flashed website replaces the interim one-page website which went online on January 1st 2020 already and briefly summarized the project, stated its objectives, expected impact and key facts (start date, funding amount, number of partners, and project duration), and listed all project partners and important contact information.

The full-flashed website contains much more detailed information about the project, important features for consortium members, trainees and interested scientists, as well as interactive features for patients and the general public. Pages aimed at disseminating the project's results are, for example, the publications page, the news page, the press coverage page, the download page, and the interactive Q & A page. An e-learning page targeted towards the project's trainees has also been prepared in order to integrate training materials and masterclass videos throughout the duration of the project.


The website's language is targeted at an educated but non-scientific general public, and its content will be updated with project news, open positions, new team members, new downloads, the web-version of the project's info-brochure, key results, new publications, meetings for scientists and events for patients, masterclass videos and other training materials on a regular basis as the project progresses. Click on the screenshot below to access & browse through the QSPainRelief project website!



2. Deliverable report

The new website was developed by concentris, and its content checked, edited and verified by the project's coordinator, Prof. Dr. Liesbeth de Lange from ULEI, and by the chair of the Impact (and Innovation) Board, Robert Carr from ISB. In comparison to the initial one-page website, it consists of the following new pages and features:


- An introductory homepage, including the most recent news & events posts and a resources tab



- 4 main navigation areas for chronic pain patients, the general public, consortium member, trainees, and interested scientists



- A contact form for every consortium member, a search function for the website, and a login function for members of the consortium to access the project's confidential intranet (Keyways)



- 24 subpages with detailed information about the project, its vision, why it matters, all consortium partner institutions, the different work packages, an interactive Q & A page for the public / study participants / chronic pain patients, links, downloads, project meetings, relevant conferences, patient events, publications, background literature, news, press coverage, an e-learning platform for QSPainRelief trainees as well as other trainees in pain research.

- The project partners are presented collectively in form of an EU-map on the homepage, and individually on separate pages in form of profile pictures, contact information and a brief textual presentation of the respective institute.


Homepage:



PROJECT PARTNERS

- Universiteit Leiden (ULEI)
Leiden, Netherlands (Coordinator)
- Alma Mater Studiorum – Università di Bologna (UNIBO)
Bologna, Italy
- Cliniques Universitaires Saint-Luc (CUSL)
Bruxelles, Belgium
- concentris research management gmbh (concentris)
Fürstentfeldbruck, Germany
- In Silico Biosciences, Inc. (ISB)
Lexington, MA, United States
- PD-value B.V. (PD-VALUE)
Houten, Netherlands
- Stichting Centre for Human Drug Research (CHDR)
Leiden, Netherlands
- Universitat Autònoma de Barcelona (UAB)
Barcelona, Spain
- Universitat Pompeu Fabra (UPF)
Barcelona, Spain
- Université Catholique de Louvain (UCL)
Louvain-la-Neuve, Belgium

Example of an individual member page:



HOME > ABOUT > MEMBERS > STICHTING CENTRE FOR HUMAN DRUG RESEARCH

CHDR
Centre for Human Drug Research


QUANTIFYING THE ANALGESIC POTENTIAL OF DRUGS IN EARLY-STAGE CLINICAL TRIALS

Centre of Human Drug Research
Zernikedreef 8
2333 CL Leiden
NETHERLANDS


[Visit website](#)

← Previous member Next member →

TEAM LEADER


Dr. Geert Jan Groeneveld
CSO & CMO at CHDR
Phone: +31 715 246 407
[SEND MESSAGE](#)


TEAM STAFF


Dr. Karen Broekhuizen
Medical Writer
Phone: +31 715 246 407
[SEND MESSAGE](#)



INSTITUTE PRESENTATION

The Centre for Human Drug Research (CHDR) in Leiden, Netherlands, is a clinical pharmacology research foundation that is involved in early phase clinical drug research. We perform clinical drug studies in collaboration with the pharmaceutical industry in many different areas, one of which is pain. On average 2-3 new analgesic

- The footer menu contains a link to the Horizon 2020 website (<https://ec.europa.eu/programmes/horizon2020/en>), the mandatory funding and dissemination acknowledgement, and prominent social media icons that lead to the project's LinkedIn and Twitter accounts.



- Until the end of the year 2020, the entire website content will be translated into 5 more languages (Dutch NL, French FR, German DE, Italian IT, and Spanish ES), as promised in the "Description of action", and made available via a language-selection function in the top-right corner of the navigation menu. This takes some time in order to ensure scientific accuracy and high quality.
- In order to comply with the European GDPR, all website visitors have to choose and consent to their cookie preferences prior to being able to browse through the website. Detailed privacy policy information is accessible on the 'Legal Disclaimer' subpage. The contact forms are protected with Google's "invisible reCaptcha", and the entire website is secured with an SSL certificate.



3. Conclusion

In conclusion, we are confident that the project website will serve as a central go-to platform for the general public, as well as chronic pain patients, study participants, and the consortium members when seeking key information about the project or wishing to contact a member of the consortium. A google analytics account will monitor the website's traffic.